Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484365 | 0.92 | P2RX7 (0.68) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9485178 | 0.92 | P2RX7 (0.79) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484296 | 0.89 | P2RX7 (0.75) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483983 | 0.88 | P2RX7 (0.69) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484447 | 0.88 | P2RX7 (0.66) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484269 | 0.87 | P2RX7 (0.74) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484512 | 0.86 | P2RX7 (0.64) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484420 | 0.86 | P2RX7 (0.83) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483316 | 0.86 | P2RX7 (0.66) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2598038 | 0.84 | P2RX7 (0.59) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5244895-A | 5-Isoquinolinesulfonamides with N substituents containing benzyl and heterocyclic groups | Hidaka, Hiroyoshi (JP) | 1993-09-14 | — | — | US | claimed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-0513691-B1 | Anti-ulcer agent | HIDAKA HIROYOSHI (JP) | 1996-07-31 | — | — | EP | disclosed |
| US-5245034-A | Compound having vessel smooth muscle relaxation activity | Hidaka, Kiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5244895-A | 5-Isoquinolinesulfonamides with N substituents containing benzyl and heterocyclic groups | Hidaka, Hiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5216150-A | Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor | Hidaka, Hiroyoshi (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0513691-A1 | Anti-ulcer agent | Hidaka, Hiroyoshi (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | P2RX7 2569/4885ALDH1A1 3179/4885SMN1; SMN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.